CHOSA presents data at ASCO validating Platin-DRP on the NanoString platform showing significant overall survival prediction in Phase III lung cancer study
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
01 June 2026 - CHOSA Oncology AB (“CHOSA” or the “Company”) today announces publication of a ASCO 2026 abstract presenting additional data demonstrating the ability of the Company’s Platin-DRP® biomarker to predict OS in advanced non-small cell lung cancer (NSCLC) using the NanoString technology.
The abstract reports significant associations between Platin-DRP® scores and overall survival (OS) in platinum-treated NSCLC patients from the randomized Phase III SPLENDOUR trial conducted by the internationally renowned lung cancer groups ETOP and EORTC.
Importantly, the validation was performed using NanoString technology, one of the most widely adopted gene expression platforms in clinical oncology, further supporting the commercial scalability and clinical applicability of CHOSA’s Platin-DRP®.
Key findings from the ASCO abstract include:
• Significant prediction of overall survival in platinum-treated advanced NSCLC patients
• Validation performed using NanoString gene expression technology
• Data generated from the randomized Phase III SPLENDOUR study conducted in collaboration with ETOP and EORTC
• Results support the ability of Platin-DRP® to identify patients more likely to benefit from platinum chemotherapy.
The newly released ASCO abstract expands upon CHOSA’s previously announced NanoString validation results, where the Company communicated that successful transfer of Platin-DRP® from Affymetrix to NanoString technology could potentially double the commercial market opportunity for the biomarker platform.
NanoString compatibility is considered strategically important because the platform is widely implemented in clinical oncology laboratories and may facilitate broader future adoption of Platin-DRP®.
“These ASCO data further strengthen the clinical evidence supporting Platin-DRP® and demonstrate that the biomarker maintains predictive performance on NanoString technology. This is an important milestone both scientifically and commercially, as it potentially enables access to a substantially broader clinical market,” said Peter Buhl Jensen, CEO of CHOSA Oncology.
Abstract title:
“mRNA-based profile to predict platinum sensitivity in NSCLC assessed by NanoString – a translational analysis of the Phase III SPLENDOUR trial conducted in collaboration with ETOP/EORTC”
The abstract is publicly available through ASCO’s website:
https://www.asco.org/abstracts-presentations/266433
The results build on CHOSA’s earlier announcement regarding NanoString validation and market expansion potential:
https://ir.chosaoncology.com/press-releases/chosa-the-market-now-doubles-for-platin-drp-which-predicts-overall-survival-in-lung-cancer-patients-based-on-nanostring-data
This information is information that CHOSA Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 20:30 CET on 1 June.
For more information please contact:
Peter Buhl Jensen, CEO
peter@chosa.bio
+ 45 21 60 89 22
About CHOSA Oncology AB
CHOSA Oncology is a precision oncology company developing Platin-DRP®, a gene expression–based biomarker that predicts response to platinum-based chemotherapy. By identifying patients most likely to benefit, CHOSA aims to improve outcomes and optimize treatment selection in cancer care.
About ETOP IBCSG Partners Foundation
The ETOP IBCSG Partners Foundation is a not-for-profit international academic research organization based in Berne, Switzerland. Established on July 1, 2021, through the merger of the European Thoracic Oncology Platform (ETOP) and the International Breast Cancer Study Group (IBCSG), the foundation aims to promote scientific exchange and advance cancer research, particularly in thoracic and breast cancers.
The foundation's mission is to answer questions that improve patients' lives, with a vision of enhancing scientific exchange on a global scale. It achieves this by implementing and promoting clinical and translational research studies, fostering collaboration among international investigators, and organizing educational events such as annual meetings and residential workshops.
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
Background
Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer therapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Platin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.
As previously announced, CHOSA is also exploring the predictive potential of Platin-DRP in those treated with carboplatin in lung cancer. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort and potentially confirm its utility across both drugs. Future research will also aim to determine whether Platin-DRP can predict the effectiveness of platinum drugs combined with PD-1/L1 inhibitors. CHOSA Oncology AB is an oncology biotechnology company led by an experienced international team with expertise in oncology, drug development, clinical trials, regulatory affairs, and business development. CHOSA intends to enter into partnership or sublicensing agreements for LiPlaCis® and the DRP®.
About Platin-DRP, a test to predict if cisplatin treatment is likely to be successful
CHOSA is focused on its Platin-DRP® drug response predictor, to which it holds worldwide rights. Platin-DRP is a validated test designed to help identify patients most likely to benefit from cis- and carboplatin treatment. Breast: Strong phase 2b data in metastatic breast cancer have shown that patients selected by DRP® responded better to treatment, had longer progression-free survival, and may also have achieved longer overall survival than patients identified as unlikely to respond well. Lung: Platin-DRP has also demonstrated its ability to predict the benefit of adjuvant cisplatin in lung cancer. Cisplatin treatment after surgery remains a gold standard that can improve cure rates, but doctors have not had a validated tool to identify which patients are most likely to benefit. This is where Platin-DRP may become a game changer, particularly in newer neoadjuvant settings where immunotherapy has shown high efficacy in combination with platinum doublets. Platin-DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to eliminate residual tumour cells. Patients with the 10% highest scores had a 3-year survival of 90%, whereas patients with the lowest 10% scores had a 3-year survival of only 40%¹. In 2026 CHOSA in collaboration with key opinion leaders in lung cancer showed the Platin-DRP in advanced clearly separated the patient with a sensitive cancer from a platin resistant tumor with a median survival of 16.9 months in the former group vs only 5.5 months in the latter2.
Immunotherapy Cisplatin and carboplatin have often been shown to activate the immune system, potentially making “cold” tumours more susceptible to PD-1 inhibitors. This synergy may be important not only in lung cancer, but also in breast cancer, bladder cancer and head & neck cancer. In the growing PD-1 inhibitor market, CHOSA’s approach may offer the ability to predict whether platin can provide synergy with PD-1 inhibition, potentially creating a meaningful advantage for treatment selection and future partners.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609 2) ESMO Open Volume 11, Supplement 3, 106773, April 2026
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.